Bristol-Myers Squibb Co (NYSE:BMY) Shares Purchased by Hedeker Wealth LLC

Hedeker Wealth LLC boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 13.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,066 shares of the biopharmaceutical company’s stock after acquiring an additional 3,230 shares during the quarter. Hedeker Wealth LLC’s holdings in Bristol-Myers Squibb were worth $1,227,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BMY. Financial Gravity Wealth Inc. bought a new position in Bristol-Myers Squibb during the 1st quarter valued at $26,000. Capital Financial Planning LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $28,000. Private Ocean LLC bought a new position in Bristol-Myers Squibb during the 1st quarter valued at $28,000. Trust Department MB Financial Bank N A bought a new position in Bristol-Myers Squibb during the 1st quarter valued at $32,000. Finally, James Investment Research Inc. boosted its stake in Bristol-Myers Squibb by 36.5% during the 1st quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 219 shares in the last quarter. Hedge funds and other institutional investors own 77.71% of the company’s stock.

Shares of Bristol-Myers Squibb stock opened at $45.69 on Wednesday. The firm has a market capitalization of $75.23 billion, a PE ratio of 11.48, a PEG ratio of 2.28 and a beta of 0.73. The stock has a fifty day simple moving average of $45.49. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. Bristol-Myers Squibb’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share. As a group, research analysts anticipate that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.41 dividend. The ex-dividend date of this dividend was Wednesday, July 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.59%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 5,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was acquired at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the transaction, the director now directly owns 27,000 shares in the company, valued at approximately $1,276,830. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the sale, the insider now directly owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Several equities research analysts have recently weighed in on BMY shares. JPMorgan Chase & Co. started coverage on Bristol-Myers Squibb in a research note on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective for the company. Barclays raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $53.00 to $55.00 in a research note on Friday, May 3rd. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Tuesday, May 7th. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a research note on Monday, May 20th. Finally, ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $55.45.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Leveraged Buyout (LBO) Explained

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.